DSGN (Design Therapeutics) EBIT per Share : $-1.10 (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Design Therapeutics EBIT per Share?

Design Therapeutics's EBIT per Share for the three months ended in Dec. 2024 was $-0.30. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.10.

During the past 3 years, the average EBIT per Share Growth Rate was -12.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was -81.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Design Therapeutics's EBIT per Share or its related term are showing as below:

DSGN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -158.8 Med: -108.1 Max: -12.2
Current: -12.2

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Design Therapeutics was -12.20% per year. The lowest was -158.80% per year. And the median was -108.10% per year.

DSGN's 3-Year EBIT Growth Rate is ranked worse than
73.73% of 1237 companies
in the Biotechnology industry
Industry Median: 7.6 vs DSGN: -12.20

Design Therapeutics's EBIT for the three months ended in Dec. 2024 was $-16.69 Mil.

Design Therapeutics EBIT per Share Historical Data

The historical data trend for Design Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Design Therapeutics EBIT per Share Chart

Design Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-0.16

-0.78

-1.21

-1.40

-1.10

Design Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.27	-0.26	-0.27	-0.29	-0.30

Design Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Design Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-62.383	/	56.587
=	-1.10

Design Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-16.694	/	56.683
=	-0.29

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.10

Design Therapeutics (NAS:DSGN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Design Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Design Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Design Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Design Therapeutics Inc (NAS:DSGN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

6005 Hidden Valley Road, Suite 110, Carlsbad, CA, USA, 92011

Website

https://www.designtx.com

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Executives

Deepa Prasad	director	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265
Arsani William	director	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
John P. Schmid	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Heather Behanna	director	C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
Rodney W Lappe	director	C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Joao Md Siffert	director, officer: President and CEO	20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Simeon George	director, 10 percent owner	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Sr One Capital Fund I Aggregator Lp	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Stella Xu	director, 10 percent owner	C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Julie Burgess	officer: Chief Accounting Officer	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Dawn Giangiulio	officer: Principal Accounting Officer	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Sean Jeffries	officer: Chief Operating Officer	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Justin Thacker	officer: Vice President, Finance	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Pratik Shah	director, officer: Executive Chairperson	3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116